{"id":"https://openalex.org/W4362555834","doi":"https://doi.org/10.1158/2159-8290.c.6549581","title":"Data from Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy","display_name":"Data from Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy","publication_year":2023,"publication_date":"2023-04-04","ids":{"openalex":"https://openalex.org/W4362555834","doi":"https://doi.org/10.1158/2159-8290.c.6549581"},"language":"en","primary_location":{"id":"doi:10.1158/2159-8290.c.6549581","doi":"https://doi.org/10.1158/2159-8290.c.6549581","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.c.6549581","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2159-8290.c.6549581","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002360335","display_name":"Zihai Li","orcid":"https://orcid.org/0000-0003-4603-927X","observed_orcids":["https://orcid.org/0000-0003-4603-927X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zihai Li","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4603-927X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032091697","display_name":"Joseph H. Azar","orcid":"https://orcid.org/0000-0001-9518-2908","observed_orcids":["https://orcid.org/0000-0001-9518-2908"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph H. Azar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5046739998","display_name":"Mark P. Rubinstein","orcid":"https://orcid.org/0000-0003-4748-0286","observed_orcids":["https://orcid.org/0000-0003-4748-0286","https://orcid.org/0000-0002-9942-7519"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark P. Rubinstein","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/4-1bb-agonist","display_name":"4-1BB agonist","score":0.9020000100135803},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.9919999837875366},{"id":"https://openalex.org/keywords/bispecific-fusion-protein","display_name":"bispecific fusion protein","score":0.9810000061988831},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.871999979019165},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7630000114440918},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.7229999899864197}],"concepts":[{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.6178193688392639},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5899113416671753},{"id":"https://openalex.org/C188198153","wikidata":"https://www.wikidata.org/wiki/Q1613840","display_name":"Limiting","level":2,"score":0.5674690008163452},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.5510254502296448},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5311226844787598},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5142590403556824},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.45569270849227905},{"id":"https://openalex.org/C2776654903","wikidata":"https://www.wikidata.org/wiki/Q2601463","display_name":"SAFER","level":2,"score":0.41469907760620117},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4055745005607605},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34934002161026},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.19594603776931763},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.11648359894752502},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0},{"id":"https://openalex.org/C38652104","wikidata":"https://www.wikidata.org/wiki/Q3510521","display_name":"Computer security","level":1,"score":0.0},{"id":"https://openalex.org/C78519656","wikidata":"https://www.wikidata.org/wiki/Q101333","display_name":"Mechanical engineering","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/2159-8290.c.6549581","doi":"https://doi.org/10.1158/2159-8290.c.6549581","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.c.6549581","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2159-8290.c.6549581","doi":"https://doi.org/10.1158/2159-8290.c.6549581","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.c.6549581","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4225266732","https://openalex.org/W4282945728","https://openalex.org/W4409626799","https://openalex.org/W4402560921","https://openalex.org/W3214300736","https://openalex.org/W3212904207","https://openalex.org/W4282964937","https://openalex.org/W4282984224","https://openalex.org/W3174658350","https://openalex.org/W4393086848"],"abstract_inverted_index":{"Summary:":[0],"Dose-limiting":[1],"toxicities":[2],"are":[3],"thought":[4],"to":[5],"temper":[6],"the":[7],"efficacy":[8],"of":[9,20],"single-agent":[10],"4-1BB":[11,38],"agonists.":[12],"To":[13],"overcome":[14],"this":[15,18],"hurdle,":[16],"in":[17],"issue":[19],"Cancer":[21],"Discovery,":[22],"Muik":[23,45],"and":[24,28,39],"colleagues":[25],"report":[26],"preclinical":[27],"clinical":[29],"studies":[30],"describing":[31],"a":[32],"first-in-class":[33],"bispecific":[34],"fusion":[35],"protein":[36],"targeting":[37],"PD-L1.":[40],"See":[41],"related":[42],"article":[43],"by":[44],"et":[46],"al.,":[47],"p.":[48],"1248":[49],"(9).":[50]},"counts_by_year":[],"updated_date":"2026-10-09T09:14:12.587421","created_date":"2023-04-06T00:00:00"}